Xeris Biopharma Reports Strong Q1 Results, Swings to Net Income, and Raises Full-Year Revenue Guidance

summarizeSummary

Xeris Biopharma reported strong first-quarter 2026 financial results, including a significant increase in product revenue and a swing to net income, leading the company to raise its full-year revenue guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Total product revenue increased 43% year-over-year to $82.5 million for the first quarter ended March 31, 2026. Recorlev net revenue nearly doubled, growing 95% year-over-year to $49.8 million.

• Achieves Net Income

  The company reported a net income of $2.2 million for Q1 2026, a significant improvement from a net loss of $9.2 million in the same period last year, building on its first net income in 2025.

• Raises Full-Year Revenue Guidance

  Xeris tightened and raised the bottom end of its full-year 2026 total revenue guidance to $380 million to $390 million, representing over 30% growth at the midpoint.

• Pipeline Advancement

  The company anticipates initiating a Phase 3 clinical trial for its XP-8121 program later in 2026, marking a significant value creation inflection point.

auto_awesomeAnalysis

Xeris Biopharma delivered a robust first quarter, demonstrating significant operational improvements and continued growth. The company's swing from a net loss to net income, coupled with substantial product revenue growth, indicates strong commercial execution. The decision to raise the bottom end of its full-year revenue guidance, following its first net income in 2025, reinforces a positive trajectory and suggests increasing confidence in its commercial portfolio, particularly Recorlev. Additionally, the anticipated Phase 3 initiation for XP-8121 later in the year provides a future value creation catalyst.